SELLAS Life Sciences Group Inc. Common Stock (SLS)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach SELLAS as a Graham-style speculation in drug development, not as a proven business. It reports no revenue in the filed periods, and it has lost money in each of the last four years. In fiscal 2025, the year ended 2025-12-31, net loss was $26.9 million, or $0.25 per diluted share. In fiscal 2024, the year ended 2024-12-31, net loss was $30.9 million, or $0.50 per share; fiscal 2023, the year ended 2023-12-31, lost $37.3 million, or $1.34 per share. More recently, fiscal Q2 2026, the quarter ended 2026-06-30, showed a $9.6 million net loss and $0.05 diluted EPS, while fiscal Q1 2026, the quarter ended 2026-03-31, lost $8.4 million and $0.05 diluted EPS. There is no revenue to anchor value. The balance sheet shows minimal debt, with D/E 0.01, but trailing free cash flow is negative $28.4 million and FCF yield is -1.1%. FairStock's 2/9 Piotroski score and 14/100 overall score confirm fragility. The Altman Z-score of 192.92 is presented as a FairStock calculation, but for a pre-revenue biotech it does not substitute for commercial proof. Valuation is demanding: at the 2026-10-13 close of $12.41, market cap is $2.5 billion, P/B is 18.25, and ROE is -39.63%. The P/E of -56.41 simply reflects losses. The Lynch category is 'none' because of four straight loss years. Any moat would have to come from clinical data and eventual drug approval, which the filed figures do not yet show. Growth is not observable in revenue, and the stock's beta of 2.52 signals wide expectations. The 52-week range of $1.39 to $15.88 shows how sentiment, not earnings, drives the quote. I would demand a margin of safety, but here intrinsic value is a guess until trials produce revenue.

In plain English: SELLAS is a small company trying to develop new cancer treatments; it has no reported revenue and has been losing money. The business looks financially weak because it burns cash, though it owes very little debt. At the latest price of $12.41 on 2026-10-13, the $2.5 billion market value looks expensive compared with its losses and reported book value, so the price depends mostly on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer